Technology
Health
Pharmaceutical

G1 Therapeutics

$22.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.48 (2.17%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell GTHX and other stocks, options, ETFs, and crypto commission-free!

About

G1 Therapeutics, Inc. Common Stock, also called G1 Therapeutics, is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. Read More The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Employees
84
Headquarters
Research Triangle Park, North Carolina
Founded
2008
Market Cap
848.12M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
364.28K
High Today
$23.25
Low Today
$22.29
Open Price
$22.29
Volume
98.01K
52 Week High
$69.57
52 Week Low
$13.87

Collections

Technology
Health
Pharmaceutical
Therapy
Cancer Prevention
Medical
Biopharmaceutical
2017 IPO

News

Yahoo FinanceMay 13

G1 Therapeutics to Present at UBS Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., May 13, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the UBS Global Healthcare Conference. The presentation will take place on Tuesday, May 21 at 4:00 p.m. ET at the Grand Hyatt New York in New York, NY. To access the live webcast presentation, please visit the Events & Presentations page within the Investors section of the G1...

28
Seeking AlphaMay 12

G1 Therapeutics, Inc. CEO Mark Velleca on Q1 2019 Results - Earnings Call Transcript

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Jeff Macdonald - Head, Investor & Public Relations Mark Velleca - President & CEO Jennifer Moses - CFO Rajesh Malik - Chief Medical Officer & SVP R&D Conference Call Participants Dane Leone - Raymond James & Associates Chad Messer - Needham & Company Harshita Polishetty - B. Riley FBR Operator Good afternoon, ladies and gentlemen, and welcome to G1 First Quarter 2019 Corporate and Fina...

17
Yahoo FinanceMay 12

Imagine Owning G1 Therapeutics And Wondering If The 48% Share Price Slide Is Justified

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Over the last month the G1 Therapeutics, Inc. (NASDAQ:GTHX) has been much stronger than before, rebounding by 39%. But that doesn't change the fact that the returns over the last year have been less than pleasing. In fact the stock is down 48% in the last year, well below the market return. Check out our latest analysis for G1 Therapeutics G1 Therapeutics didn't have any revenue in ...

17

Earnings

-$0.72
-$0.66
-$0.61
-$0.55
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.